Background Hepatitis C virus (HCV) infection has major health impact worldwide and is a significant cause of chronic liver disease. In Egypt, HCV is highly endemic (up to 15% of the population); 91% of the patients are infected with genotype 4. Searching for new predictors of response to therapy is mandatory to decrease the cost and the adverse effects of current therapy.
Introduction
Hepatitis C virus (HCV) is the cause of a significant proportion of cases of chronic liver disease, hepatocellular carcinoma, and death because of liver disease. On the basis of the current prevalence of infection and anticipated rates of progression, morbidity and mortality as well as the costs of treatment for HCV infection are expected to increase significantly in the next two decades [1] .
Searching for new predictors of response to therapy is mandatory to decrease the cost and the adverse effects of current therapy [2] . Currently, the existing association among the different virus genotypes and the level of fat upload in the liver as well as the various levels of response to the antiviral conventional treatment are well known [3] [4] [5] . Different links with lipidic profile alterations have generated particular interest as they have offered, at least partially, explanations on the mechanism of viral operation [6, 7] .
Insulin resistance (IR) is associated with the presence of HCV and it determines a low rate of response to the standard antiviral therapy [8] . IR expressed in hepatocytes is a result of alterations in a group of serologic and local factors as well as an altered adiponectin profile. Adiponectin is the most abundant adipokine in plasma and its production decreases in the context of obesity and IR. It has anti-inflammatory properties and plays a role in increasing hepatocyte sensitivity to the gluconeogenesis inhibition mediated by insulin [9] . Adipokines and hyperinsulinemia have been considered as determining factors of the extent of fibrosis and of the unresponsiveness to pegylated interferon (PEG IFN), the result and duration of the antiviral treatment depending on the patient's metabolic and nutritional status and the viral genotype [10, 11] . However, recently, attention has been focused on adiponectin and its changes in different types of chronic liver disease. Its relation to hepatic fibrosis and IR in posthepatitis liver disease is not clear [12] .
Leptin is a circulating 16-kDa nonglycosylated protein [13] ; its levels are related to the adipose tissue mass [14] . Leptin has been implicated in many actions including liver fibrogenesis [15] [16] [17] [18] . Serum leptin levels have been found to be higher in patients with chronic hepatitis C (CHC) and in particular in those with more severe fibrosis or cirrhosis [19] ; however, the results are conflicting [20] [21] [22] .
The aim of this study was to clarify the usefulness of the clinical use of serum leptin, adiponectin, and IR as a predictor of response to treatment in hepatitis C virus genotype 4 (HCVG4).
Methods

Population samples
This study was carried out on 100 consecutive patients with chronic HCVG4 infection who were candidates for treatment with PEG IFN-a and ribavirin. The inclusion criteria were as follows: naive patients 18-60 years of age, HCV RNA positive with abnormal alanine aminotransferase (ALT), liver biopsy performed within 6 months before enrollment, and a diagnosis of CHC without cirrhosis. The exclusion criteria were as follows: those who are not fit for IFN therapy (coinfection with hepatitis B virus, alcohol intake, clinically evident liver cirrhosis, any end organ failure, hematological diseases, major psychiatric disorder, pregnant, and breast-feeding women). Informed consent was obtained from all participants before enrollment in the study. The study was carried out in accordance with the principles of the Declaration of Helsinki, and its appendices, and local and national laws.
All the patients were subjected to a clinical assessment. Height and weight were determined at baseline and BMI was calculated as weight in kg divided by height in m 2 . Before starting therapy, laboratory investigations included complete liver profile, kidney function, international Ratio, and complete blood count. HCV PCR was quantified in all patients' sera using real time PCR (Stratagene, Foster City, California, USA); accordingly, they were classified into low (< 100 000 IU/ml), medium (100 000-1 000 000 IU/ml), and high (> 1 000 000 IU/ml), and as known more than 90% of Egyptian patients have HCVG4 [23, 24] . a-Fetoprotein and HCV antibody were determined using Axyam (Abbot, New York, USA). Serum levels of adiponectin, leptin, and fasting insulin were determined using the ELISA test. Blood samples were obtained in the morning after 12 h of fasting. They were centrifuged and serum was separated, and then stored at -801C before use. IR was determined by homeostasis model assessment (HOMA) using the following equation [25] : HOMA = fasting insulin (mU/ml) Â fasting glucose (mmol/l)/22.5. HOMA values more than 2.7 were considered to indicate IR; this cutoff corresponds to the upper quartile of a previously published control Italian population [26] . Abdominal ultrasound was performed for all the enrolled patients using a Toshiba (Japan) machine with a 3.5 MHz convex probe; patients were examined after at least 8 h of fasting. Percutaneous liver biopsy was performed under ultrasound guidance using 16-G needles. Specimens at least 2.5 cm in length, including a minimum of 12 portal tracts, were considered reliable for adequate grading and staging using a modified Knodell's score. Liver biopsies were assessed by a single pathologist who was blinded to the clinical data; the Metavir classification was used for the assessment of necroinflammation and stage of fibrosis. All the patients were treated with PEG IFN-a-2a, 180 mg/week subcutaneously, plus ribavirin (1000-1200 mg orally/day on the basis of body weight).
Statistical methods
Continuous, normally distributed variables are summarized as mean±SD. Categorical and ordinal data are presented as frequencies and percentages. Differences between the means of continuous variables were assessed using Student's t-test. The association of a sustained virological response (SVR) with potential risk factors was assessed using the w 2 and Fisher's exact tests where appropriate. Those factors showing a significant association in bivariate analysis or considered to be important factors irrespective of bivariate analysis results were included in multivariate logistic regression analysis. A ROC was constructed and the area under the curve (AUC) was calculated to determine whether adiponectin is capable of predicting a SVR. P values of less than 0.05 were considered statistically significant. Analyses were carried out using SPSS version 15.0 (SPSS Inc., Chicago, Illinois, USA).
Results
The baseline characteristics of 100 chronic HCVG4 patients enrolled in the study are shown in Table 1 ; there were 68 men and 32 women, mean±SD age 40.9±7.8 years and mean±SD BMI 28.3±10 kg/m 2 . The mean value of trans-aminases±SD was: aspartate aminotransferase (AST) = 63.5±20.1, ALT = 55.8±15.1); the mean±SD of a-fetoprotein was 10.3±4.9. Number of patients with low, medium, and high HCV viral load were 17, 51, and 32, respectively. The mean±SD serum leptin level was 9.4±5.5, that of adiponectin was 17.4±7.0, and IR was 35.0±17.2. The overall hepatic grade of inflammation was 5.9±1.1 and stage of fibrosis was 3.3±0.8. Of 100 patients, 56 showed a SVR, whereas 44 showed no response or relapse; no patient withdrew from therapy because of side-effects and no patients received less than 80% of the therapeutic schedule. Their demographic, laboratory, and histological parameters are shown in Table 2 . Both groups were age, sex, and HCV viral load matched; BMI was significantly higher in the nonresponder group compared with the SVR group (35.3±8.1 vs. 22.8±7.6; P < 0.001). High serum leptin was statistically significant in the nonresponder group compared with the SVR group (13.4±4.7 vs. 6.2±3.7; P = 0.012), whereas low serum adiponectin was statistically significant in the nonresponder group versus the SVR group (11.6±5.2 vs. 22.0±4.4; P < 0.001). IR was significantly higher in the nonresponder group (48.0±15.1 vs. 24.8±10.8; P < 0.001).
In terms of the histological features, there were significantly higher grades of inflammation and stages of fibrosis in nonresponders compared with those who achieved an SVR (6.2±1.2 and 3.6±0.7 vs. 5.6±1.0 and 3.0±0.8; P = 0.005 and P < 0.001, respectively).
A multivariate comparison of variables between patients with and without an SVR is shown in Tables 3 and 4 . By logistic regression, BMI [odds ratio (OR) 6.5; 95% confidence interval (CI) 1.7-23.4; P = 0.004], serum leptin (OR 27.8; 95% CI 6.3-123.9; P r 0.001), AST (OR 1.06; 95% CI 1.04-1.09, P r 0.001), IR (OR 1.15; 95% CI 1.09-1.21, P r 0.001), histological activity index (OR 1.77; 95% CI 1.18-2.65; P = 0.006), and fibrosis (OR 2.93; 95% CI 1.56-5.49; P = 0.001) were found to be independent negative predictors of SVR, whereas serum adiponectin (OR 0.74; 95% CI 0.68-0.82; P r 0.001) was found to be an independent positive predictor of SVR.
To evaluate the suitability of pretreatment levels of leptin, adiponectin, and IR to predict patients with a SVR, it was found that at a cutoff point of 13.75 for pretreatment adiponectin, the sensitivity and specificity of adiponectin for the SVR were 92.86 and 86.86%, respectively. The AUC for adiponectin was 0.879 (95% CI 0.802-0.956; P < 0.001) as shown in Fig. 1 . For the serum leptin and IR, there were no significant AUCs with no sensitivity or specificity (AUC for leptin was 0.10, 95% CI 0.03-0.17 and AUC for IR was 0.09, 95% CI 0.03-0.14).
Discussion
SVR, defined as undetectable HCV RNA in serum 24 weeks after the end of therapy [27] , varies primarily according to the HCV genotype, which is the single most important parameter affecting the rate of cure. In our study, 56% of the patients with chronic HCVG4 showed an SVR, which is in agreement with other studies in which SVR rates of 55-60% have been reported [28, 29] ; in some studies, it reaches 69% [30, 31] . However, studies Values are presented as mean±SD unless indicated otherwise. AFP, a-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; IR, insulin resistance; OR, odds ratio. *P < 0.05 is significant. carried out in Europe [32] [33] [34] have shown that the SVR rates in Africans or Europeans with chronic HCVG4 treated with PEG IFN-a plus ribavirin are lower than those obtained in studies carried out in the Middle East. This may be influenced by multiple factors; some are related to HCV itself as patients infected with HCV-G4a had higher SVR rates than those infected with HCV-G4d [34] . Other factors are unrelated to HCV: genetic factors, age, sex, BMI, stage of liver disease, and some comorbidities such as IR, which affect both liver fibrosis progression and response to therapy [35] . The results of our study further confirm that in patients with CHC, high BMI has been associated with a lower SVR rate; furtheremore, certain studies have found that BMI more than 30 is an independent risk factor for nonresponse to antiviral therapy in chronic HCV [36] , and this can be attributed to the following: first, BMI has been shown to correlate with the degree of steatosis found in hepatitis C [37] . Steatosis leads to an increase in lipid deposits within cells [38] , which may cause a functional disturbance by decreasing the contact area between the drugs and the hepatocytes containing the virus [39] . Second, in obese individuals, there may be a reduction in the initial absorption of a drug administered subcutaneously because of an increase in subcutaneous fat. Third, the structural property of PEG IFNs is such that its size precludes rapid uptake into the vascular system, but large proteins (> 15 kDa) injected subcutaneously are primarily taken up by the lymphatic system, and obese individuals are known to have poor lymphatic circulation [40] ; this could potentially lead to lower serum levels of PEG IFN, thus reducing the likelihood of a successful antiviral response.
Leptin concentration, which is a proinflammatory adipokine, is increased in obese patients. Leptin stimulates Th1 responses [41] , which favors an SVR in CHC patients receiving antiviral therapy [42] . This is not contradictory to the presence of a high baseline leptin level in our CHCG4 patients without SVR, because upregulation of leptin secretion may result from peripheral leptin resistance, thus suggesting that leptin resistance (rather than increased effects) may underlie hyporesponsiveness to IFN-a [43] . Leptin resistance in these patients may be caused by abnormal leptin transport and disturbances in ObR signaling, including overexpression of the suppressor of cytokine signaling-3 (SOCS3), an agent that inhibits leptin signaling [44] . Univariate regression analysis of our patients showed statistically significant high baseline serum leptin levels in nonresponder chronic HCVG4 patients; however, in multivariate logistic regression analysis, high baseline leptin level was a negative prognostic factor for response to antiviral therapy [9] , but with small AUC. Another factor that may be related to the reduced response to IFN-a is IR; increasing levels of IR are associated with reduced rates of an initial virological response [45] [46] [47] and SVR [48] [49] [50] [51] [52] . Our study also provides further evidence that IR impairs sustained response to antiviral treatment in genotype 4-infected patients. This negative association has been reported to occur both in patients infected with the genotype 1 [48, 49, 52] and in those with genotypes 2 and 3 [51] . A reasonable explanation might be the involvement of HCV in the development of IR, a theory supported by many previous reports [53] . The levels of the SOCS3, a factor promoting the degradation of the insulin receptor substrate-1, thus leading to impaired insulin signaling and IR, have been reported to be increased in cells expressing the HCV core protein [53] as well as in the liver of CHC patients not responding to antiviral therapy [54] . SOCS3 is also a negative regulator of IFN-a signaling [55] . Thus, SOCS3 upregulation by HCV may represent a first molecular link between a reduced response to IFN-a and IR. Other evidence suggests that IR is associated with severe fibrosis and poor response to treatment in patients with CHC [48, 56, 57] , which was proved in our study. Moreover, there may be an interaction between serum leptin and IR on hepatic fibrogenesis and poor response to IFNribavirin therapy in genotype 4, as documented in previous reports on genotype 1 [58] , and as already proposed by Romero-Gomez et al. [48] , HOMA-IR could represent the best host marker to predict an SVR in genotype 1-infected patients.
Another adipokine that plays a role in chronic hepatitis is adiponectin; it has hepatoprotective and antifibrogenic effects in cases of hepatic injury and protects against liver steatosis [59] . In the current study, there was a significant decrease in serum adiponectin in CHCG4 patients with SVR and it represent a positive prognostic factor for response to IFN-ribavirin therapy in CHCG4 in multivariate regression analysis, which can be explained by the fact that adiponectin, both total and high molecular weight isoforms, increased the production of antiviral cytokine IFN-g by polymorph nuclear cells from HCV-infected patients, in addition to attenuation of IL-6 production [60] . Although IFN-g is a proinflammatory cytokine, it is crucial in establishment of the antiviral state both by inhibition of viral replication [61] and by induction of proteins involved in regulating the innate and adaptive immune response [62] . In conclusion, BMI, pretreatment high leptin, and IR are negative predictors for SVR and pretreatment low adiponectin is an independent positive predictor for SVR in HCVG4.
